Mein Warenkorb

Canine IL-13 R alpha 2 Protein, His Tag (MALS verified)

User Reviews
Product Number/Spec
Price
Menge
IL2-C52H6-100ug
€310.00
IL2-C52H6-1mg
€2265.00
ETA of in-stock products:3 business days
Gesamtanzahl Product Amount0

Product Details

  • Synonym

    IL13RA2, CD213A2, CT19, IL-13R, IL13BP

  • Source

    Canine IL-13 R alpha 2, His Tag (IL2-C52H6) is expressed from human 293 cells (HEK293). It contains AA Ser 22 - Thr 338 (Accession # Q95LF0-1).

    Predicted N-terminus: Ser 22

    Request for sequence
  • Molecular Characterization

    IL-13 R alpha 2 Structure

    Other Tags and Version Biotin & Other Labeled Version

    This protein carries a polyhistidine tag at the C-terminus.

    The protein has a calculated MW of 40.3 kDa. The protein migrates as 45-55 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

  • Endotoxin

    Less than 1.0 EU per μg by the LAL method / rFC method.

  • Purity

    >90% as determined by SDS-PAGE.

    >95% as determined by SEC-MALS.

  • Formulation

    Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.

    Contact us for customized product form or formulation.

  • Reconstitution

    Please see Certificate of Analysis for specific instructions.

    For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

  • Storage

    For long term storage, the product should be stored at lyophilized state at -20°C or lower.

    Please avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. -20°C to -70°C for 12 months in lyophilized state;
    2. -70°C for 3 months under sterile conditions after reconstitution.
  • ACRO Quality Management System

    1. QMS(ISO, GMP)
    2. Quality Advantages
    3. Quality Control Process

Kunden haben auch angesehen

Data Display

  • SDS-PAGE

    IL-13 R alpha 2 SDS-PAGE

    Canine IL-13 R alpha 2, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90%.

  • SEC-MALS

    IL-13 R alpha 2 SEC-MALS

    The purity of Canine IL-13 R alpha 2, His Tag (Cat. No. IL2-C52H6) is more than 95% and the molecular weight of this protein is around 50-60 kDa verified by SEC-MALS.

    Report
  • Bioactivity-ELISA

     IL-13 R alpha 2 ELISA

    Immobilized Canine IL-13 R alpha 2, His Tag (Cat. No. IL2-C52H6) at 1 μg/mL (100 μL/well) can bind Monoclonal Anti-IL-13 R alpha 2 Antibody, Mouse IgG1 with a linear range of 0.2-2 ng/mL (QC tested).

    Protocol

User Reviews
Publish Comment

Background Introduction

Interleukin-13 receptor subunit alpha-2 is also known as IL13Rα2, IL13Ra2 cluster of differentiation 213A2, CD213A2, CT19, IL-13R, IL13BP, and is a membrane bound protein that in humans is encoded by the IL13RA2 gene. IL13Rα2 is closely related to IL13Rα1, a subunit of the interleukin-13 receptor complex. This protein binds IL13 with high affinity, but lacks any significant cytoplasmic domain, and does not appear to function as a signal mediator. It is, however able to regulate the effects of both IL13 and IL4, despite the fact it is unable to bind directly to the latter. It is also reported to play a role in the internalization of IL13. IL13Rα2 is a component of the cell surface receptors, however, the majority exists in intracellular pools and in soluble form, and thus plays an opposite role as a potent IL13 antagonist compared with IL13Rα1. It also functions as an inhibitor of IL4-dependent pathway probably through the physical interaction between the short intracellular domain of and cytoplasmic domain of IL13Rα2 and the IL4Rα chain. In spite of the failed STAT signaling function, IL13Rα2 dose induce TGF-beta production and fibrosis. Additionally, IL13Rα2has been reported to be abundantly and specifically overexpressed in glioblastoma multiforme.

Frontier Progress

 
Drug Development Progress
  • English Name:

    Interleukin-13 receptor subunit alpha-2

  • Category:

  • Listed Drugs Count:

    0 Details

  • Clinical Drugs Count:

    9 Details

  • Highest R&D Stage:

    Phase 1 Clinical

Drug Candidate Licensing
More
  • Basic Product Information
  • Product Details
  • Kunden haben auch angesehen
  • Data Display
  • User Reviews
  • Hintergrund
Kontaktieren Sie uns